Axsome Therapeutics Inc (AXSM)

Axsome Therapeutics (AXSM) Stock Price & Analysis


AXSM Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$20.63 - $82.00
Previous Close$74.29
Average Volume (3M)1.27M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$227.52M
Total Debt (Recent Filing)$94.33M
Price to Earnings (P/E)-18.3
Next EarningsFeb 27, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-4.07
Shares Outstanding43,426,162
Standard Deviation0.41
10 Day Avg. Volume808,803
30 Day Avg. Volume1,268,101
Price to Book (P/B)38.68
Price to Sales (P/S)126.09
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-22.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside59.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Axsome Therapeutics’s price range in the past 12 months?
Axsome Therapeutics lowest stock price was $20.63 and its highest was $82.00 in the past 12 months.
    What is Axsome Therapeutics’s market cap?
    Currently, no data Available
    When is Axsome Therapeutics’s upcoming earnings report date?
    Axsome Therapeutics’s upcoming earnings report date is Feb 27, 2023 which is in 23 days.
      How were Axsome Therapeutics’s earnings last quarter?
      Axsome Therapeutics released its earnings results on Nov 07, 2022. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$1.05 by -$0.02.
        Is Axsome Therapeutics overvalued?
        According to Wall Street analysts Axsome Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Axsome Therapeutics pay dividends?
          Axsome Therapeutics does not currently pay dividends.
          What is Axsome Therapeutics’s EPS estimate?
          Axsome Therapeutics’s EPS estimate is -$1.12.
            How many shares outstanding does Axsome Therapeutics have?
            Axsome Therapeutics has 43,426,163 shares outstanding.
              What happened to Axsome Therapeutics’s price movement after its last earnings report?
              Axsome Therapeutics reported an EPS of -$1.07 in its last earnings report, missing expectations of -$1.05. Following the earnings report the stock price went down -0.473%.
                Which hedge fund is a major shareholder of Axsome Therapeutics?
                Among the largest hedge funds holding Axsome Therapeutics’s share is Fairmount Funds Management Llc. It holds Axsome Therapeutics’s shares valued at 85M.


                  Axsome Therapeutics Stock Smart Score

                  The Axsome Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Axsome Therapeutics Inc

                  Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Elanco Animal Health
                  Harmony Biosciences Holdings
                  Prestige Consumer Healthcare
                  Intra-Cellular Therapies

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis